SME IPO · NSE SME · Closed, awaiting listing
ABH Healthcare IPO
ABH Healthcare Limited is closed and awaiting listing, offered in a price band of ₹96 to ₹102 per share, in lots of 2400 shares. Every figure below is taken from the issue's own filings and exchange disclosures.
Issue details
- Price band
- ₹96 – ₹102
- Lot size
- 2400 shares
- Minimum investment
- ₹2,44,800
- Issue size
- ₹34.98 Cr
- Fresh issue
- ₹34.98 Cr
- Offer for sale
- —
- Opens
- 24 Aug 2026
- Closes
- 27 Aug 2026
- Listing date
- 31 Aug 2026
- Registrar
- Bigshare Services Pvt. Ltd.
- Symbol
- ABH
One lot of 2400 shares at the upper band price of ₹102 is ₹2,44,800 — the smallest retail application this issue accepts.
Lead managers: Fedex Securities Pvt.Ltd.
Subscription status
How many times the issue has been applied for, by investor category, as reported by the exchange at 27 Aug 2026, 07:05 pm IST.
ABH Healthcare IPO — subscription by category| Category | Times subscribed |
|---|
| Qualified institutional buyers (QIB) | 0.00× |
|---|
| Non-institutional investors (NII / HNI) | 0.00× |
|---|
| Retail individual investors | 1.27× |
|---|
| Total | 0.00× |
|---|
Grey market premium (GMP)
- Latest reported GMP
- ₹0
- Implied over upper band
- 0.00%
- As of
- 17 Aug 2026, 09:05 pm IST
How the reported premium has moved. The trend matters more than any single reading — a premium that is drifting down into the close is a different signal from one holding firm.
ABH Healthcare IPO — reported GMP history| Reported at | GMP |
|---|
| 17 Aug 2026, 09:05 pm IST | ₹0 |
|---|
| 17 Aug 2026, 08:05 pm IST | ₹0 |
|---|
| 17 Aug 2026, 07:06 pm IST | ₹0 |
|---|
Grey Market Premium is an unofficial, unregulated over-the-counter datapoint reported by third parties. It is not a price, a forecast, or an indication of listing gains, and is not investment advice.
Reported financials
As disclosed in the offer document. Figures in ₹ crore unless the filing states otherwise.
ABH Healthcare — financials from the offer document| PAT | Assets | Expense | Revenue | Period Ended |
|---|
| ₹0.09 | ₹26.27 | ₹3.38 | ₹3.50 | 2022 |
|---|
| ₹0.71 | ₹32.96 | ₹28.45 | ₹29.61 | 2023 |
|---|
| ₹1.66 | ₹51.35 | ₹39.19 | ₹41.39 | 2024 |
|---|
| ₹3.32 | ₹61.03 | ₹31.78 | ₹36.42 | Dec 2024 |
|---|
Strengths disclosed in the offer document
- The company is led by a qualified and experienced management team with proven execution capabilities.
- The company has a robust digital infrastructure to improve operational efficiencies and patient experience.
- The company aims to attract and retain qualified and experienced clinicians by offering competitive compensation and quality services.
- The company has a strong brand recognition and a commitment to providing comprehensive clinical care through a collaborative, multidisciplinary team.
- The company has a diversified operations across clinical specialties, payor mix, and hospitals.
- The company has a track record of stable operating and financial performance and growth.
Risk factors disclosed in the offer document
- The company's revenues are significantly dependent on its only hospital in Ferozepur, Punjab, making it vulnerable to adverse economic or political circumstances in the region.
- The company is significantly dependent on its key personnel, including its promoters and senior management, and any loss of or inability to attract or retain such persons could adversely affect its business.
- The company faces competition from other hospitals and healthcare facilities, and an inability to compete effectively could materially and adversely affect its business and results of operations.
- The company is vulnerable to failures of its information technology system, which could adversely affect its business, financial condition, results of operations, and cash flows.
- The company's hospitals are susceptible to risks arising on account of fire and other incidents, which may materially and adversely affect its business, cash flows, financial condition, and results of operations.
- The company may be subject to worker unrests and increased wage expenses, which could materially and adversely affect its business, financial condition, results of operations, and cash flows.
- The company's operations are subject to high working capital requirements, and an inability to maintain an optimal level of working capital may impact its operations adversely.
These are the company's own disclosures, not Alphave's assessment. Read the offer document →
What this page will not tell you
- Whether to apply
- Alphave is NISM-certified, not a SEBI-registered research analyst. There is no rating, verdict or recommendation on this issue anywhere on this page.
- What it will list at
- Nobody knows, and GMP is not a forecast of it. It is an unofficial over-the-counter quote reported by third parties, shown here with its source time so you can judge how stale it is.
- Your allotment
- Allotment is decided by the registrar (Bigshare Services Pvt. Ltd.) after the issue closes. Track the whole calendar in the IPO Centre.
← All current and upcoming IPOs · Open the interactive ABH Healthcare terminal →